Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PTX35-001 A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients With Advanced Solid Tumors Refractory to Standard of Care

Next Previous
X
Search
Trial Profile

PTX35-001 A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients With Advanced Solid Tumors Refractory to Standard of Care

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTX 35 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Pelican Therapeutics; Scorpius Holdings

    • Most Recent Events

    • 06 Feb 2024 According to a NightHawk Biosciences media release, the NightHawk Biosciences has changed its name to Scorpius Holdings.
    • 20 Nov 2023 According to a NightHawk Biosciences media release, PTX-35 expense decreased by $0.5 million primarily due to the discontinued development of PTX-35 in the third quarter of 2022.
    • 20 Nov 2023 Status changed from active, no longer recruiting to discontinued, according to a NightHawk Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top